Chronic Graft-Versus-Host Disease (cGVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Chronic Graft-Versus-Host Disease (cGVHD) lasts more than three months after transplantation and is the most common late complication of allogeneic HSCT, accounting for approximately 25% of pediatric patients. Chronic GVHD is the primary cause of nonrelapse mortality and morbidity in long-term HSCT survivors. cGVHD typically manifests with multiorgan pathology and historically has been defined temporally as GVHD that occurred later than 100 days post-SCT. Chronic GVHD has a wide prevalence ranging from 6% to 80%, depending on factors such as donor type, recipient age, and the source of the transplanted hemopoietic cells. Chronic GVHD is diagnosed by distinguishing it from acute GVHD, having at least one diagnostic clinical sign of chronic GVHD, or having at least one distinctive manifestation confirmed by pertinent biopsy or other relevant tests in the same or another organ, and ruling out other possible diagnoses. Chronic GVHD symptoms can appear in the skin, oral and gut mucosa, eyes, lungs, female genitalia, and connective tissue.
• The incidence of Chronic Graft-Versus-Host Disease (cGVHD) ranges from 14 to 16 cases per million population in the USA.

Thelansis’s “Chronic Graft-Versus-Host Disease (cGVHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Graft-Versus-Host Disease (cGVHD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Chronic Graft-Versus-Host Disease (cGVHD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Chronic Graft-Versus-Host Disease (cGVHD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Chronic Graft-Versus-Host Disease (cGVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Chronic Graft-Versus-Host Disease (cGVHD), Chronic Graft-Versus-Host Disease (cGVHD) market outlook, Chronic Graft-Versus-Host Disease (cGVHD) competitive landscape, Chronic Graft-Versus-Host Disease (cGVHD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)